Davey B. Daniel MD

Oncology•Chattanooga, TN

Physician

Join to View Full Profile

605 Glenwood DrSuite 200Chattanooga, TN 37404
Phone+1 423-698-1844
Fax+1 423-624-2226

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
Duke University HospitalResidency, Internal Medicine, 1999 - 2002
Johns Hopkins University School of MedicineClass of 1999

Certifications & Licensure

GA State Medical License 2005 - 2025
TN State Medical License 2005 - 2025
NC State Medical License 1999 - 2006
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012

Clinical Trials

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01
Unknown status
Phase 3
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Start of enrollment: 2015 Jul 01
Terminated
Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Start of enrollment: 2021 Nov 03
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.
Victor T G Lin, Esprit Ma, Neha Jain, Zhiyu Xia, Danny Sheinson
The Oncologist. 2025-05-08
83 citations
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Ying Cheng, David R Spigel, Byoung Chul Cho, Konstantin K Laktionov, Jian Fang
The New England Journal of Medicine. 2024-10-10
5 citations
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang
The Oncologist. 2024-06-03

Journal Articles

Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC
David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine

Press Mentions

OneOncology Appoints Dr. Michael Byrne as Medical Director for Cellular TherapyJuly 7th, 2025
“Who Really Needs Chemotherapy” for Lung Cancer? New Test May Help Answer Key QuestionJuly 1st, 2025
Cancer Biomarker Testing: Teaming with Physicians to Ensure Access EverywhereFebruary 7th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member